101 related articles for article (PubMed ID: 8152278)
21. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
22. [Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer].
Ikawa T; Eura M; Fukiage T; Murakami H; Yamasaki S; Fukuda K; Fukushima M; Arishima S; Maehara T; Ishikawa T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1438-47. PubMed ID: 2786378
[TBL] [Abstract][Full Text] [Related]
23. [Isolation and expansion of glioma-infiltrating lymphocytes in vitro: an analysis of their surface phenotypes and antitumor activities].
Sawamura Y
Hokkaido Igaku Zasshi; 1991 Nov; 66(6):868-78. PubMed ID: 1783372
[TBL] [Abstract][Full Text] [Related]
24. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
25. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
[TBL] [Abstract][Full Text] [Related]
26. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
Frost P; Caliliw R; Belldegrun A; Bonavida B
Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
[TBL] [Abstract][Full Text] [Related]
27. Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.
Kass R; Bellone S; Palmieri M; Canè S; Bignotti E; Henry-Tillman R; Hutchins L; Cannon MJ; Klimberg S; Santin AD
Breast Cancer Res Treat; 2003 Aug; 80(3):275-85. PubMed ID: 14503800
[TBL] [Abstract][Full Text] [Related]
28. Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.
Leess FR; Bredenkamp JK; Lichtenstein A; Mickel RA
Laryngoscope; 1989 Dec; 99(12):1255-61. PubMed ID: 2601539
[TBL] [Abstract][Full Text] [Related]
29. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures.
Topalian SL; Kasid A; Rosenberg SA
J Immunol; 1990 Jun; 144(11):4487-95. PubMed ID: 2160503
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
[TBL] [Abstract][Full Text] [Related]
31. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG
Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
[TBL] [Abstract][Full Text] [Related]
32. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
33. Human natural killer cells: a comprehensive review.
Sinkovics JG; Horvath JC
Int J Oncol; 2005 Jul; 27(1):5-47. PubMed ID: 15942642
[TBL] [Abstract][Full Text] [Related]
34. [A new therapeutic concept in the treatment of metastatic cancers of the kidney: the TIL (tumor infiltrating lymphocytes)].
Peyret C
J Urol (Paris); 1991; 97(2):63-71. PubMed ID: 2071925
[TBL] [Abstract][Full Text] [Related]
35. Suppression of lymphokine-activated killer cell generation by tumor-infiltrating lymphocytes.
Chakraborty NG; Sporn JR; Pasquale DR; Ergin MT; Mukherji B
Clin Immunol Immunopathol; 1991 Jun; 59(3):407-16. PubMed ID: 2029793
[TBL] [Abstract][Full Text] [Related]
36. Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.
Curti BD; Longo DL; Ochoa AC; Conlon KC; Smith JW; Alvord WG; Creekmore SP; Fenton RG; Gause BL; Holmlund J
J Clin Oncol; 1993 Apr; 11(4):652-60. PubMed ID: 8257476
[TBL] [Abstract][Full Text] [Related]
37. At the bedside: adoptive cell therapy for melanoma-clinical development.
Weber JS
J Leukoc Biol; 2014 Jun; 95(6):875-82. PubMed ID: 24732024
[TBL] [Abstract][Full Text] [Related]
38. [Study on adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL) for renal cell carcinoma--amplification of IL-2-elicited TIL proliferation by OKT3-monoclonal antibody].
Hayakawa M; Sisido S; Higa I; Koyama Y; Hatano T; Osawa A
Nihon Hinyokika Gakkai Zasshi; 1990 Jan; 81(1):103-9. PubMed ID: 2304307
[TBL] [Abstract][Full Text] [Related]
39. [Local injection of BRM-activated killer cells into an abdominal wall tumor].
Ebina T
Gan To Kagaku Ryoho; 2013 Nov; 40(11):1507-9. PubMed ID: 24231704
[TBL] [Abstract][Full Text] [Related]
40. Functional and phenotypic analyses of interleukin 2-activated tumor-infiltrating lymphocytes.
Yamaue H; Tanimura H; Tsunoda T; Iwahashi M; Tani M; Tamai M; Inoue M
Biotherapy; 1990; 2(3):247-59. PubMed ID: 1698423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
